Bookmark and Share

Michael  E Kleinberg
 

Michael E Kleinberg M.D., Ph.D.

Academic Title: Associate Professor
Primary Appointment: Medicine
Additional Title(s): Director, Infectious Diseases Cancer Center Program, University of Maryland Greenebaum Cancer Center
MKLEINBE@umaryland.edu
Location: UMMC, Room N9E05
Phone: (410) 328-2679
Fax: (410) 328-6896

Personal History:

My clinical interests are the infectious complications of patients with cancer treated in the University of Maryland Greenebaum Cancer Center. Cancer patients may be treated with chemotherapy, immune modulators or bone marrow/stem cell transplantation. The host immune system is impaired to varying degrees depending on the type of malignancy and the way in which it is treated. The most profoundly immunosuppressed cancer patients are frequently infected, often by pathogens that are not virulent to people defended by normal immune systems.

My academic interests are development of methods to optimize treatment of infections in complicated neutropenic patients and in bone marrow/stem cell transplant recipients. The complexity of infection management in these patients defies standard drug/bug models since patients must often be treated empirically for some time before it is possible to make accurate diagnoses. These patients are best treated through algorithm-driven treatment models where treatment choices are reevaluated repeatedly as diagnostic testing data and observations of patients responses are used to refine the initial approaches and to arrive at the best outcomes.


Publications:

Peng, G., Huang, J., Boyd, M., and Kleinberg, M.E., 2003. Properties of Phagocyte NADPH Oxidase p47-phox Mutants with Unmasked SH3 Domains: Full Reconstitution of Oxidase Activity in a Semi-recombinant Cell-free System Lacking Arachidonic Acid. Biochem. J. 373:221-229.

Kleinberg, M. 2004. Routine Anti-Bacterial Prophylaxis is Not Indicated in Neutropenic Patients with Hematologic Malignancies. J. National Comprehensive Cancer Network 2:445-451.

Kleinberg, M. 2005. Aspergillosis in the CLEAR Outcomes Trial: Working Toward a Real-World Clinical Perspective. Medical Mycology 43:S289-S294.

Johnson, M.D., Kleinberg, M., Danziger, L., and Ostrosky-Zeichner, L. 2005. Pharmacoeconomics of Antifungal Pharmacotherapy – Challenges and Future Directions. Expert Opinion Pharmacotherapy 6:2617.

Kleinberg, M. What is the Current and Future Status of Conventional Amphotericin B? Internat. J. Antimicrob. Agents. (in press).